Back

Local delivery of cell surface-targeted immunocytokines programs systemic anti-tumor immunity

Santollani, L.; Zhang, Y. J.; Maiorino, L.; Palmeri, J. R.; Stinson, J. A.; Duhamel, L. R.; Qureshi, K.; Suggs, J. R.; Porth, O. T.; Pinney, W.; Al Msari, R.; Wittrup, K. D.; Irvine, D. J.

2024-01-03 immunology
10.1101/2024.01.03.573641 bioRxiv
Show abstract

Cytokine therapies are potent immunotherapy agents but exhibit severe dose-limiting toxicities. One strategy to overcome this involves engineering cytokines for intratumoral retention following local delivery. Here, we develop a localized cytokine therapy that elicits profound anti-tumor immunity by engineered targeting to the ubiquitous leukocyte receptor CD45. We designed CD45-targeted immunocytokines (CD45-Cyt) that, upon injection, decorated the surface of leukocytes in the tumor and tumor-draining lymph node (TDLN) without systemic exposure. CD45-Cyt therapy eradicated both directly treated tumors and untreated distal lesions in multiple syngeneic mouse tumor models. Mechanistically, CD45-Cyt triggered prolonged pSTAT signaling and reprogrammed tumor-specific CD8+ T cells in the TDLN to exhibit an anti-viral transcriptional signature. CD45 anchoring represents a broad platform for protein retention by host immune cells for use in immunotherapy.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.